Theranostics
13.3
Impact Factor
Global reach, higher impact
Theranostics 2025; 15(16):8704-8705. doi:10.7150/thno.117883 This issue Cite
Erratum
Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
Liping Zhong1,2*, Wei Shi3*, Lu Gan1*, Xiuli Liu1*, Yu Huo1, Pan Wu1, Zhikun Zhang1, Tao Wu2, Hongmei Peng2, Yong Huang1, Yongxiang Zhao1, Yulin Yuan1,4 
, Zhiming Deng2 , Hongliang Tang3,5
1. National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi 530021, China. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi 530021, China.
2. The First People's Hospital of Changde City, Changde, Hunan 41500, China
3. Department of Oncology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi 530023, China.
4. Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China.
5. Department of Scientific Research, The Affiliated Fangchenggang Hospital, Guangxi University of Chinese Medicine, Fangchenggang, Guangxi 538001, China.
* These authors contributed equally to this work.
Published 2025-8-5
Citation:
Zhong L, Shi W, Gan L, Liu X, Huo Y, Wu P, Zhang Z, Wu T, Peng H, Huang Y, Zhao Y, Yuan Y, Deng Z, Tang H. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. Theranostics 2025; 15(16):8704-8705. doi:10.7150/thno.117883. https://www.thno.org/v15p8704.htm
Other stylesCorrected-article in Theranostics, Volume 11, 6393
The authors apologize for errors in the originally published version of this article that require correction. Mistaken images were used in Figure 5A (e), Figure 7 (Heart of the hEND-CD3/BiTE group), and Supplementary Figures S4A, S4C, and S6d. The authors have corrected the mistakenly used images and declare that these corrections do not change the conclusions of this article. The authors sincerely apologize to the journal and its readers for any confusion this may have caused. The corrected versions are provided below.
Figure A
Corrected figure for original Figure 5A (e), Figure 7 (Heart of the hEND-CD3/BiTE group), and Supplementary Figure S6d.
Figure B
Corrected figure for original Supplementary Figure S4A and C.
Author contact
Corresponding authors: Hongliang Tang (tanghl204edu.cn), Zhiming Deng (dengzhmcdcom), Yulin Yuan (yuanyulincom).
Citation styles
APA
Zhong, L., Shi, W., Gan, L., Liu, X., Huo, Y., Wu, P., Zhang, Z., Wu, T., Peng, H., Huang, Y., Zhao, Y., Yuan, Y., Deng, Z., Tang, H. (2025). Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. Theranostics, 15(16), 8704-8705. https://doi.org/10.7150/thno.117883.
ACS
Zhong, L.; Shi, W.; Gan, L.; Liu, X.; Huo, Y.; Wu, P.; Zhang, Z.; Wu, T.; Peng, H.; Huang, Y.; Zhao, Y.; Yuan, Y.; Deng, Z.; Tang, H. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. Theranostics 2025, 15 (16), 8704-8705. DOI: 10.7150/thno.117883.
NLM
Zhong L, Shi W, Gan L, Liu X, Huo Y, Wu P, Zhang Z, Wu T, Peng H, Huang Y, Zhao Y, Yuan Y, Deng Z, Tang H. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. Theranostics 2025; 15(16):8704-8705. doi:10.7150/thno.117883. https://www.thno.org/v15p8704.htm
CSE
Zhong L, Shi W, Gan L, Liu X, Huo Y, Wu P, Zhang Z, Wu T, Peng H, Huang Y, Zhao Y, Yuan Y, Deng Z, Tang H. 2025. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. Theranostics. 15(16):8704-8705.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See https://ivyspring.com/terms for full terms and conditions.